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Abstract
Metabolic regulation has been implicated in the pathogenesis of inflammatory diseases. NADPH 
oxidase 4 (NOX4), a source of cellular superoxide anion, has multiple biological functions that 
may be of importance in inflammation, and in the pathogenesis of human metabolic diseases, 
including diabetes. However, the mechanisms by which NOX4-dependent metabolic regulation 
impacts the innate immune response remain unclear. Here, we show that deficiency of NOX4 
resulted in reduced expression of carnitine palmitoyltransferase 1A (CPT1A), which is a key 
mitochondrial enzyme in the fatty acid oxidation (FAO) pathway. The reduced FAO resulted in 
less activation of the nucleotide binding domain, leucine-rich repeat-containing receptor (NLR), 
pyrin domain-containing-3 (NLRP3) inflammasome in human and mouse macrophages. In 
contrast, NOX4 deficiency did not inhibit the activation of the NLR family, CARD domain 
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containing 4 (NLRC4), the NLRP1, or the absent in melanoma 2 (AIM2) inflammasomes. We also 
found that inhibition of FAO by etomoxir suppressed NLRP3 inflammasome activation. 
Furthermore, Nox4-deficient mice displayed significant reduction of caspase-1 activation and 
interleukin (IL)-1β and IL-18 production and improved survival in a mouse model of NLRP3-
mediated Streptococcus pneumoniae (S. pneumoniae) infection. The pharmacologic inhibition of 
NOX4 by either GKT137831, currently in phase 2 clinical trials, or VAS-2870 attenuated NLRP3 
inflammasome activation. Our results suggest that NOX4-mediated FAO promotes NLRP3 
inflammasome activation.
The NLRP3 inflammasome, a molecular platform that modulates innate immune functions 
by activation of caspase-1, catalyzes the proteolytic processing and secretion of IL-1β and 
IL-18 in immune cells1,2. Cellular metabolites have been linked to NLRP3 inflammasome 
activation3–5. We have previously reported that cellular metabolic pathways, including 
glycolysis and fatty acid synthesis, are associated with NLRP3 inflammasome activation in 
macrophages under pro-inflammatory conditions6,7. Notably, fatty acid metabolism has been 
linked to NLRP3 inflammasome activation4,5,7 ,a process that is implicated in metabolic 
diseases such as obesity-derived diabetes or insulin resistance8. As a mechanism for the 
utilization of fatty acids, FAO is a major bioenergetic pathway, which is upregulated under 
conditions of prolonged fasting, exercise or metabolic stress9,10. Among the enzymes in the 
FAO pathway, the reduced activity of CPT1A, which is essential for the proper transport and 
oxidation of long chain fatty acids (LCFAs) in mitochondria may promote type 2 diabetes 
and insulin resistance11,12. Recently, mitochondrial NOX4 has been implicated in oxidative 
stress and mitochondrial function in the diabetic kidney and heart13–21. Currently, the role of 
NOX4 in regulating cellular metabolism during NLRP3 inflammasome activation remains 
incompletely understood. In this study we sought to identify the mechanisms by which 
NOX4 regulates the NLRP3 inflammasome, which is a key mediator of macrophage-
dependent inflammation through regulation of mitochondria-dependent metabolic pathways.
RESULTS
Deficiency of NOX4 suppresses NLRP3 inflammasome activation
To investigate the function of NOX4 in NLRP3 inflammasome activation, we analyzed 
whether genetic deficiency of NOX4 could suppress the secretion of IL-1β and IL-18 in 
lipopolysaccharide (LPS)-primed bone marrow-derived macrophages (BMDMs) in response 
to specific NLRP3 inflammasome activators, including nigericin, ATP and silica. Nox4−/− 
BMDMs displayed significantly lower IL-1β and IL-18 secretion (Fig. 1a) in response to 
nigericin, ATP and silica compared to wild-type (WT) BMDMs, while tumor necrosis factor 
(TNF)-α was unchanged (Fig. 1a). In contrast, deficiency of NOX4 had no effect on the 
secretion of IL-1β and IL-18 in response to muramyldipeptide (MDP), a NLRP1 
inflammasome activator, or flagellin, a NLRC4 inflammasome activator (Fig. 1a). IL-1β 
secretion was not changed in Nox4−/− BMDMs treated with poly(dA:dT), an AIM2 
inflammasome activator, relative to WT BMDMs (Fig. 1b). Notably, Nox4−/− BMDMs 
displayed lower expression of cleaved caspase-1 and cleaved IL-1β in response to nigericin 
and ATP, relative to WT BMDMs, while pro-IL-1β expression was unchanged (Fig. 1c and 
Supplementary Fig. 1a).
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Furthermore, we also investigated the role of NOX4 in NLRP3 inflammasome activation in 
human cells. Thus, to examine whether genetic deficiency of NOX4 could suppress 
caspase-1 activation, we used two independent NOX4-targeted gRNAs to delete human 
NOX4 in primary human macrophages via CRISPR technology and found that the activation 
of caspase-1 and IL-1β cleavage in response to LPS and nigericin were lower compared to 
transduction with the control plasmid (Fig. 1d). Consistently, the secretion of IL-1β and 
IL-18 in response to nigericin and ATP were significantly lower when cells were transduced 
with the two NOX4-targeted gRNAs relative to the control plasmid (Fig. 1e), while TNF-α 
was unchanged (Supplementary Fig. 1b). Next, we investigated the role of NOX4 in a mouse 
model of S. pneumoniae lung-infection. S. pneumoniae, a leading cause of pneumonia and 
meningitis, activates the NLRP3 inflammasome through its secreted pore-forming toxin 
pneumolysin22,23. The levels of IL-1β, IL-18 and TNF-α (Fig. 1f), NOX4 protein 
expression, and caspase-1 activation (Fig. 1g) in lung tissues of WT mice were higher after 
S. pneumoniae infection relative to vehicle-treated mice. Notably, the levels of IL-1β and 
IL-18 (Fig. 1f) and caspase-1 activation (Fig. 1g) in lung tissues were significantly lower in 
S. pneumoniae-infected Nox4−/− mice compared to infected WT mice, whereas TNF-α was 
comparable (Fig. 1f). Moreover, Nox4−/− mice were more resistant to S. pneumoniae-
induced mortality at 150 h post-infection than WT mice (Fig. 1h). Furthermore, the plasma 
levels of IL-1β and IL-18 in response to LPS challenge in vivo was significantly lower in 
Nox4−/− mice compared to WT mice, whereas TNF-α was unchanged (Supplementary Fig. 
1c). These results suggest that NOX4 regulates NLRP3 inflammasome activation in vitro 
and in vivo.
NOX4 regulates FAO during NLRP3 inflammasome activation
We next investigated the underlying molecular mechanism by which NOX4 regulates 
NLRP3 inflammasome activation. Among the six isoform genes of Nox tested (Nox1–4 and 
dual oxidase (Duox)1–2), we identified that Nox4 gene expression was higher in response to 
ATP in LPS-primed WT BMDMs, relative to BMDMs treated with LPS alone or ATP alone 
or untreated BMDMs, while the expression of the other Nox isoform genes were not 
specifically regulated by LPS and ATP stimulation (Supplementary Fig. 1d). Furthermore, 
we found that NOX4 protein was preferentially expressed in mitochondria and its expression 
was markedly higher in response to nigericin and ATP stimulation in LPS-primed WT 
BMDMs, relative to LPS alone, or control (Fig. 2a). Moreover, NOX4 protein expression 
was increased in response to nigericin and ATP in a time and dose-dependent manner in 
LPS-primed WT BMDMs (Supplementary Fig. 1e,f), while LPS alone did not induce NOX4 
expression (Supplementary Fig. 1g). Consistently, treatment with silica and MSU, as well as 
A. hydrophila aerolysin, representative of particulate and bacterial toxin inducers of NLRP3, 
respectively, resulted in higher NOX4 protein expression and IL-1β secretion in LPS-primed 
WT BMDMs (Supplementary Fig. 1h,i).
Next, we examined whether NOX4-derived reactive oxygen species (ROS) could regulate 
cellular metabolism during NLRP3 inflammasome activation. Nox4−/− BMDMs had 
significantly lower mitochondrial ROS (mtROS) production in response to LPS and 
nigericin relative to WT BMDMs (Fig. 2b). As ROS is associated with FAO in myoblasts24, 
we analyzed the regulation of FAO by NOX4 during NLRP3 inflammasome activation. We 
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observed that the uptake of free fatty acids (FFAs) including LCFAs and poly-unsaturated 
fatty acids (PUFAs), were significantly higher in response to LPS and ATP in WT BMDMs, 
relative to LPS alone, or control (Supplementary Fig. 2a). FFAs levels were significantly 
lower in Nox4−/− BMDMs in response to LPS and nigericin relative to WT BMDMs (Fig. 
2c). Consistently, the protein expression of LCFA transporter cluster of differentiation 36 
(CD36), which facilitates the cellular uptake of LCFAs such as palmitate and stearate25, was 
lower in Nox4−/− BMDMs in response to LPS and nigericin compared to WT BMDMs 
(Supplementary Fig. 2b).
As FFAs are broken down and utilized by FAO for release of energy9, we evaluated whether 
NOX4 could regulate FAO during NLRP3 inflammasome activation. We measured the 
oxidation of fatty acids by monitoring cellular oxygen consumption rate (OCR) with 
palmitate-BSA treatment, as an FAO substrate9,26. The OCR was higher in response to 
nigericin stimulation in LPS-primed WT BMDMs compared to LPS alone or untreated 
control and this relative response to LPS and nigericin was higher in response to palmitate-
BSA treatment (Fig. 2d and Supplementary Fig. 2c). Nox4−/− BMDMs had lower OCR in 
response to palmitate-BSA compared to WT BMDMs after LPS and nigericin treatments 
(Fig. 2d and Supplementary Fig. 2c). In contrast to Nox4−/− BMDMs, the activation of FAO 
by palmitate-BSA resulted in higher caspase-1 activation, IL-1β cleavage (Fig. 2e and 
Supplementary Fig. 2d) and secretion of IL-1β and IL-18 (Fig. 2f) in response to nigericin 
and ATP in LPS-primed WT BMDMs relative to control, whereas TNF-α was unchanged in 
both WT and mutant BMDMs (Fig. 2f). Similar to palmitate-BSA, stearic acid-BSA 
treatment, one of the most common saturated fatty acids27, resulted in higher caspase-1 
activation, IL-1β cleavage (Supplementary Fig. 2e,f) and secretion of IL-1β and IL-18 
(Supplementary Fig. 2g) in response to nigericin and ATP relative to control, while TNF-α 
was unchanged (Supplementary Fig. 2g). Nox4−/− BMDMs had lower caspase-1 activation, 
IL-1β cleavage (Supplementary Fig. 2e,f) and secretion of IL-1β and IL-18 (Supplementary 
Fig. 2g) in response to stearic acid-BSA than WT BMDMs.
As the oxidation of FAs by FAO generates acetyl-CoA, which fuels the tricarboxylic acid 
cycle (TCA) cycle8,9, the levels of acetyl-CoA were higher in response to either nigericin or 
palmitate-BSA and nigericin in WT BMDMs, relative to Nox4−/− BMDMs (Fig. 2g). Since 
the ECAR, as an index of glycolytic rate, was comparable between WT and Nox4−/− 
BMDMs, lower acetyl-CoA production in Nox4−/− BMDMs was not affected by glycolysis 
(Supplementary Fig. 2h). In contrast, the protein expression of glucose-6-phosphate 
dehydrogenase (G6PD), the rate-limiting enzyme of the pentose phosphate pathway28, was 
comparable between WT and Nox4−/− BMDMs in response to LPS and nigericin stimulation 
(Supplementary Fig. 2i).
Next, we investigated whether NOX4-dependent FAO could regulate the oligomerization of 
the adaptor apoptosis-associated speck-like protein containing a caspase recruitment domain 
(ASC), which is required for NLRP3-dependent caspase-1 activation29,30. The formation of 
ASC monomers and higher complexes (Fig. 2h) and speck formation (Fig. 2h) induced by 
LPS and nigericin stimulation was greater in WT BMDMs than in Nox4−/− BMDMs. 
Furthermore, NOX4 overexpression resulted in higher levels of FFA and acetyl-CoA in 
response to nigericin in LPS-primed WT peritoneal macrophages compared to control (Fig. 
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2i). Moreover, NOX4 overexpression resulted in higher caspase-1 activation, IL-1β cleavage 
(Fig. 2j) and secretion of IL-1β and IL-18 (Fig. 2j) in response to LPS and nigericin relative 
to control, while TNF-α was unchanged (Fig. 2j). In the absence of LPS priming, NLRP3 
overexpression supported caspase-1 activation in response to nigericin or ATP 
(Supplementary Fig. 3a), and this effect was lower in Nox4−/− BMDMs compared to WT 
BMDMs (Supplementary Fig. 3b). These results suggest that NOX4 regulates FAO during 
NLRP3 inflammasome activation.
NOX4 regulates CPT1A during NLRP3 inflammasome activation
We next investigated the targets of NOX4 in the regulation of FAO during NLRP3 
inflammasome activation. Notably, Nox4−/− BMDMs displayed lower protein expression of 
CPT1A, which is a key enzyme for mitochondrial FAO31, in response to LPS and nigericin 
relative to WT BMDMs (Fig. 3a), while the protein expression of CPT1C and acyl-
coenzyme A oxidase 1 (ACOX1), which is a key enzyme of peroxisomal FAO32, were 
comparable (Fig. 3a). Since K+ efflux is increased by specific NLRP3 inflammasome 
activators33, we investigated whether K+ efflux could regulate NOX4 and CPT1A expression 
during NLRP3 inflammasome activation. First, we analyzed the regulation of NOX4 by K+ 
efflux. The gene expression levels of Nox4 in response to nigericin were significantly lower 
in the presence of high extracellular [K+] in LPS-primed WT BMDMs compared to control 
(Fig. 3b). Consistently, the induction of NOX4 and CPT1A protein expression, caspase-1 
activation, IL-1β cleavage and the secretion of IL-1β (Fig. 3c and Supplementary Fig. 3c) in 
response to nigericin were lower in the presence of high extracellular [K+] in LPS-primed 
WT BMDMs relative to control, while TNF-α was unchanged (Supplementary Fig. 3c). 
Similarly, treatment with glyburide, an inhibitor of ATP-sensitive K+ (KATP) channels34, 
resulted in lower protein expression of NOX4 and CPT1A, caspase-1 activation, IL-1β 
cleavage (Supplementary Fig. 3d) and secretion of IL-1β (Supplementary Fig. 3e) in 
response to nigericin relative to control, while TNF-α was unchanged (Supplementary Fig. 
3e). In contrast, the higher expression of NOX4 and CPT1A in response to LPS and 
nigericin were not altered in Nlrp3−/− BMDMs compared to WT BMDMs (Supplementary 
Fig. 3f).
To investigate the molecular mechanism by which NOX4 regulates the expression of 
CPT1A, we analyzed the role of NOX4-derived mtROS in regulating CPT1A expression 
during NLRP3 inflammasome activation. Treatment with Mito-TEMPO, a specific 
scavenger of mitochondrial superoxide35, resulted in lower protein expression of CPT1A, 
caspase-1 activation and IL-1β cleavage in response to nigericin in LPS-primed WT 
BMDMs compared to control (Fig. 3d). Consistently, Mito-TEMPO treatment resulted in 
significantly lower induction of OCR by palmitate-BSA (Fig. 3e and Supplementary Fig. 3g) 
and levels of FFA (Fig. 3f) in response to nigericin compared to control. In contrast, the 
protein expression of PPAR-γ coactivator-1α (PGC-1α), which is a key transcription factor 
that regulates the expression of proteins involved in fatty acid uptake and oxidation36, was 
comparable between Nox4−/− and WT BMDMs (Supplementary Fig. 3h). Consistently, the 
gene expression of Cpt1a was not changed in response to LPS and nigericin in Nox4−/− 
BMDMs compared to WT BMDMs (Supplementary Fig. 3i). These results suggest that 
NOX4-derived mtROS is critical for the regulation of CPT1A protein expression.
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Inhibition of FAO suppresses NLRP3 inflammasome activation
To examine whether genetic deficiency of Cpt1a could suppress caspase-1 activation, we 
used two independent Cpt1a-targeted gRNAs against mouse Cpt1a and CRISPR technology 
in WT BMDMs. Transduction with Cpt1a-targeted gRNAs resulted in a lower degree of 
activation of caspase-1, IL-1β cleavage (Fig. 4a), and secretion of IL-1β and IL-18 (Fig. 4b) 
in response to nigericin and ATP compared to the control plasmid, while TNF-α was 
unchanged (Fig. 4b). Similarly, the activation of caspase-1, cleaved IL-1β (Supplementary 
Fig. 4a), and the secretion of IL-1β and IL-18 (Supplementary Fig. 4b) in response to 
nigericin and ATP were lower in response to two independent Cpt1a shRNAs against mouse 
Cpt1a relative to control shRNA in WT peritoneal macrophages, while TNF-α was 
unchanged (Supplementary Fig. 4b). Moreover, the production of acetyl-CoA in response to 
nigericin and ATP were lower after transduction with two independent Cpt1a shRNAs 
compared to control shRNA (Supplementary Fig. 4c). Consistently, palmitate-BSA-induced 
activation of caspase-1, cleaved IL-1β (Supplementary Fig. 4d) and the secretion of IL-1β 
and IL-18 (Supplementary Fig. 4e) in response to nigericin and ATP were lower after 
transduction with Cpt1a shRNA, while TNF-α was unchanged (Supplementary Fig. 4e). 
NLRP3-dependent ASC oligomerization in response to LPS and nigericin was lower after 
transduction with a Cpt1a-targeted gRNA relative to the control plasmid (Fig. 4c). 
Furthermore, CPT1A overexpression resulted in higher caspase-1 activation, IL-1β cleavage 
(Supplementary Fig. 5a) and secretion of IL-1β and IL-18 (Supplementary Fig. 5b) in 
response to nigericin in LPS-primed BMDMs relative to control, while TNF-α was 
unchanged (Supplementary Fig. 5b). The inhibition of caspase-1 activation, IL-1β cleavage 
(Fig. 4d) and secretion of IL-1β and IL-18 (Fig. 4e) were reversed by overexpression of 
CPT1A in Nox4−/− BMDMs compared to control, while TNF-α was unchanged (Fig. 4e).
Moreover, treatment with etomoxir, a specific inhibitor of CPT137, resulted in significantly 
less secretion of IL-1β and IL-18 in response to nigericin, ATP and silica in LPS-primed WT 
BMDMs compared to vehicle control (Supplementary Fig. 5c), while TNF-α was 
unchanged (Supplementary Fig. 5c). In contrast, the secretion of IL-1β and IL-18 by MDP, 
flagellin or poly(dA:dT) stimulation was unchanged by etomoxir (Supplementary Fig. 5c). 
Consistently, the activation of caspase-1 and IL-1β cleavage in response to nigericin and 
ATP was lower in response to etomoxir relative to vehicle control (Supplementary Fig. 5d). 
Similar with Cpt1a knockdown, etomoxir treatment resulted in lower palmitate-BSA-
induced activation of caspase-1, cleaved IL-1β (Fig. 4f) and secretion of IL-1β and IL-18 
(Fig. 4g) in response to nigericin and ATP compared to vehicle control, while TNF-α was 
unchanged (Fig. 4g). These results suggest that FAO is required for NLRP3 inflammasome 
activation in response to pro-inflammatory stimuli.
Pharmacological targeting of NLRP3 inflammasome activation
We examined the effects of pharmacologic inhibition of NOX4 on NLRP3 inflammasome 
activation. Inhibition of NOX4 activity by GKT137831, a potent dual NOX1/4 inhibitor, 
currently in phase 2 trials38, resulted in significantly lower secretion of IL-1β and IL-18 in 
response to nigericin, ATP and silica in LPS-primed peritoneal macrophages compared to 
vehicle control (Fig. 5a), while TNF-α was unchanged (Fig. 5a). GKT137831 dose-
dependently lowered IL-1β secretion in response to nigericin relative to vehicle control, 
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while TNF-α was unchanged (Fig. 5b). Moreover, GKT137831 treatment resulted in lower 
activation of caspase-1 and cleaved IL-1β (Supplementary Fig. 6a) and secretion of IL-1β 
and IL-18 (Supplementary Fig. 6b) in LPS-primed WT BMDMs in response to nigericin and 
ATP compared to vehicle control, while TNF-α was unchanged (Supplementary Fig. 6b). In 
contrast, the secretion of IL-1β and IL-18 by MDP or flagellin stimulation was unchanged 
by GKT137831 (Fig. 5a). GKT137831 treatment resulted in significantly lower mtROS 
production (Fig. 5c and Supplementary Fig. 6c), CPT1A protein expression (Fig. 5d), 
induction of OCR by palmitate-BSA (Fig. 5e and Supplementary Fig. 6d) and levels of FFA 
and acetyl-CoA (Fig. 5f and Supplementary Fig. 6e) in response to nigericin relative to 
vehicle control. Furthermore, GKT137831 treatment resulted in lower palmitate-BSA-
induced activation of caspase-1, cleaved IL-1β (Supplementary Fig. 6f) and secretion of 
IL-1β and IL-18 (Fig. 5g) in response to nigericin compared to vehicle control, while TNF-
α was unchanged (Fig. 5g). GKT137831 treatment resulted in significantly lower plasma 
levels of IL-1β and IL-18 in response to LPS challenge in vivo in WT mice relative to 
vehicle control, whereas TNF-α was unchanged (Supplementary Fig. 6g). Notably, 
GKT137831 prophylactically lowered the levels of IL-1β and IL-18 (Fig. 5h) and caspase-1 
activation (Supplementary Fig. 6h) by S. pneumoniae infection in WT lung tissues compared 
to vehicle control, while TNF-α was comparable (Fig. 5h). These results suggest that 
GKT137831 reduces NLRP3 inflammasome activation in vitro and in vivo.
As GKT137831 has dual specificity for NOX1/438, we examined the effects of either NOX4 
or NOX1 inhibition on NLRP3 inflammasome activation. VAS-2870, a specific NOX4 
inhibitor10, significantly lowered IL-1β secretion in response to nigericin, ATP and silica in 
LPS-primed WT peritoneal macrophages, compared to vehicle control (Supplementary Fig. 
7a). In contrast, VAS-2870 had no effect on the secretion of IL-1β in response to MDP, 
flagellin or poly(dA:dT) compared to vehicle control (Supplementary Fig. 7a). VAS-2870 
treatment resulted in lower caspase-1 activation, IL-1β cleavage (Supplementary Fig. 7b) 
and secretion of IL-1β and IL-18 (Supplementary Fig. 7c) in LPS-primed WT BMDMs in 
response to nigericin and ATP relative to vehicle control, while TNF-α was unchanged 
(Supplementary Fig. 7c). Moreover, VAS-2870 treatment resulted in lower mtROS 
production (Fig. 6a and Supplementary Fig. 7d), CPT1A protein expression (Fig. 6b), 
induction of OCR by palmitate-BSA (Fig. 6c and Supplementary Fig. 7e), levels of FFA and 
acetyl-CoA (Fig. 6d and Supplementary Fig. 7f) in response to nigericin relative to vehicle 
control in LPS-primed WT BMDMs. Consistently, VAS-2870 treatment lowered palmitate-
BSA-induced caspase-1 activation, IL-1β cleavage (Supplementary Fig. 7g) and secretion of 
IL-1β and IL-18 (Fig. 6e) in response to nigericin compared to vehicle control, while TNF-α 
was unchanged (Fig. 6e).
In contrast, inhibition of NOX1 activity by ML171, a specific NOX1 inhibitor10, did not 
affect caspase-1 activation (Supplementary Fig. 8a) and secretion of IL-1β, IL-18 and TNF-
α in LPS-primed WT peritoneal macrophages in response to nigericin and ATP 
(Supplementary Fig. 8b,c) compared to control. Notably, GKT137831 and VAS-2870 
resulted in lower caspase-1 activation, IL-1β cleavage (Fig. 6f,g) and the secretion of IL-1β 
and IL-18 (Fig. 6h) in response to nigericin and ATP relative to vehicle control in LPS-
primed primary human macrophages, while TNF-α was unchanged (Supplementary Fig. 
8d). Similar to GKT137831, VAS-2870 treatment significantly lowered plasma levels of 
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IL-1β and IL-18 in response to LPS challenge in vivo in WT mice compared to vehicle 
control, whereas TNF-α was unchanged (Supplementary Fig. 8e).
Moreover, VAS-2870 prophylactically lowered the levels of IL-1β and IL-18 during S. 
pneumoniae infection in WT lung tissues compared to vehicle control (Fig. 6i), while TNF-
α was comparable (Fig. 6i). Furthermore, we examined the therapeutic effects of VAS-2870 
on the survival of WT mice after S. pneumoniae infection (Supplementary Fig. 8f). As the 
expression of IL-1β is significantly higher at 6 h in S. pneumoniae-infected WT BMDMs 
relative to uninfected BMDMs18, we treated WT mice therapeutically with VAS-2870 12 h 
after S. pneumoniae infection (Supplementary Fig. 8f). VAS-2870 treatment increased the 
survival of WT mice after S. pneumoniae infection at 150 h post-infection compared to 
vehicle control (Supplementary Fig. 8f). In contrast, VAS-2870 did not change the levels of 
IL-1β, IL-18 and TNF-α by S. pneumoniae infection in Nox4−/−lung tissues relative to WT 
lung tissues (Supplementary Fig. 8g). These results suggest that NOX4 is the pharmacologic 
target in the pathogenesis of S. pneumoniae.
DISCUSSION
Obesity-induced metabolic diseases, such as insulin resistance or type 2 diabetes, are linked 
to inflammasome activation8. High-fat diet (HFD)-derived fatty acids are important 
contributors to type 2 diabetes39,40. Recent studies suggest that HFD or FFAs induce NLRP3 
inflammasome activation in adipose tissues and macrophages4,8,41. Although the role of 
fatty acids in NLRP3 inflammasome activation has been demonstrated, the molecular targets 
that trigger oxidation or utilization of fatty acids during NLRP3 inflammasome activation 
are not well understood. Our findings provide a molecular mechanism by which NOX4-
dependent activation of FAO via CPT1A is critical for NLRP3 inflammasome activation by 
stimuli such as ATP and nigericin. Consistent with our findings, overload of FFAs, such as 
palmitate, increases NLRP3 inflammasome activation4. Of note, this previous study 
indicates that inhibition of AMP-activated protein kinase (AMPK) can promote NLRP3 
inflammasome activation by LPS and FFAs such as palmitate, but not by NLRP3 
inflammasome activators used in our study such as ATP and nigericin4. Consistently, our 
previous study showed that the function of AMPK is not changed during NLRP3 
inflammasome activation by LPS and ATP6. Since AMPK serves as one of the central 
regulators of cellular energy metabolism42, AMPK may modulate FAO and other metabolic 
pathways associated with NLRP3 inflammasome activation, though its role in the NOX4-
dependent inflammasome regulation remains unclear at present.
In this report, we demonstrate that NOX4-dependent regulation of FAO promotes the 
activation of the NLRP3 inflammasome. We also demonstrate that FAO via CPT1A is 
required for NLRP3 inflammasome activation. Furthermore, we show that genetic and 
pharmacologic inhibition of NOX4 suppresses NLRP3 inflammasome activation in primary 
human macrophages. Fatty acid metabolism differentially regulates both the priming and 
activation steps associated with NLRP3 inflammasome regulation in response to pro-
inflammatory stimuli4,5,7. We have previously reported that fatty acid synthesis is required 
for the priming step in NLRP3 inflammasome regulation7. Here, we have demonstrated that 
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NOX4-dependent FAO is required for NLRP3-dependent ASC oligomerization and speck 
formation during NLRP3 inflammasome activation.
FAO is essential for energy homeostasis and is mainly regulated by mitochondrial FAO via 
CPT143. The metabolic function of CPT1 is involved in the regulation of insulin secretion in 
pancreatic β-cells44,45. Similarly, the high FFAs levels of plasma are linked to insulin 
resistance46,47. Consistent with these previous studies, the mitochondrial NOX4 is up-
regulated in diabetes16. Our results indicate that CPT1A–mediated FAO could be a potential 
pharmacologic target of NOX4 in cellular metabolic pathways. Consistent with previous 
studies4,48–50, our results suggest that NOX4-dependent FAO activation might be a 
metabolic pathway for inflammasome regulation related to the dysfunction of insulin 
signaling.
Although potential small molecule inhibitors (e.g., β-hydroxybutyrate, MCC950) of the 
NLRP3 inflammasome have been identified5,51, further work will be needed to identify their 
precise mechanisms of action in advance of their clinical development. Here, we describe a 
mechanism whereby NOX4-dependent CPT1A activation promotes NLRP3 inflammasome 
activation. Our findings suggest that NOX4 and CPT1A may represent molecular targets of 
therapeutic inhibitors of the NLRP3 inflammasome. Since our results demonstrate the 
potential of the NOX1/4 inhibitor GKT137831, currently already in phase 2 human clinical 
trials, as an NLRP3 inflammasome inhibitor, we anticipate the GKT137831 inhibitor to be 
more appealing for use in inflammatory metabolic human diseases in the future. 
Furthermore, our results also indicate that NOX4 may represent a pharmacologic target in 
the treatment of pneumonia.
In conclusion, these findings demonstrate that the metabolic function of NOX4 could be a 
therapeutic target in metabolic diseases where NLRP3-mediated inflammation is implicated 
in the pathogenesis.
ONLINE METHODS
General experimental approaches
No samples, mice or data points were excluded from the reported analyses. Samples were 
not randomized to experimental groups. Mouse experiments and analyses were not 
performed in a blinded fashion.
Mice
The Nox4−/− mice were from Jackson laboratory. C57BL/6 and Nox4−/− mice were 
described previously52. The Nox4−/− mice were genotyped using standard PCR of tail DNA. 
All animal experimental protocols were approved by the Institutional Animal Care and Use 
Committee (protocol #: 2013-0108; Weill Cornell Medical College, New York, New York, 
USA).
Infection of Streptococcus pneumoniae
Streptococcus pneumoniae (S. pneumoniae) (ATCC 6303, ATCC, Manassas, VA) was grown 
on 10% sheep blood agar plates (BD Biosciences) overnight or for 4–24 h in brain heart 
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infusion (BHI) broth (BD Biosciences). Colony forming units (CFU) were assessed by 
dilution of samples in BHI and titers were determined by colony counts × dilution. WT and 
Nox4−/− mice (male, 8–10 weeks old) were anesthetized with isoflurane (5% for induction 
and 2% for maintenance) prior to intranasal instillation with 1 × 103 CFU of S. pneumoniae 
(50 µl volume in PBS). After 24 h, the mice were sacrificed. The protein expression and the 
levels of IL-1β, IL-18 and TNF-α in lung tissues from WT and Nox4−/− mice were 
measured by immunoblot analysis and ELISA. For the mortality study, WT and 
Nox4−/−mice (male and female, 7–9 weeks old) were anesthetized with isoflurane (5% for 
induction and 2% for maintenance) prior to intranasal instillation with 1 × 108 CFU of S. 
pneumoniae (50 µl volume in PBS). For S. pneumoniae infection experiments, in order to 
achieve 90% power with a two-tailed significance level (P value) of 0.05, we selected a 
minimum of 15 mice per group.
LPS challenge
The WT and Nox4−/− mice (male, 8–10 weeks old) were injected intraperitoneally with 
Escherichia coli LPS (10 mg/kg) (L4130, Sigma-Aldrich) or PBS. After 24 h, the mice were 
sacrificed. The plasma levels of IL-1β, IL-18 and TNF-α from mice were measured by 
ELISA. The WT mice were injected intraperitoneally (i.p.) with VAS-2870 (10 mg/kg), 
GKT137831 (20 mg/kg) or vehicle control (DMSO) 3 h before i.p. injection of Escherichia 
coli LPS (10 mg/kg) (L4130, Sigma-Aldrich) or PBS.
Reagents and antibodies
LPS (Escherichia coli) (tlrl-pelps), MDP (tlrl-mdp) and flagellin (Salmonella typhimurium) 
(tlrl-stfla) was from Invivogen. ATP (A2383), nigericin (N7143), poly(dA:dT) (P0883), A. 
hydrophila aerolysin (H9395) and Glyburide (G2539) were from Sigma-Aldrich. VAS-2870 
(BML-EI395-0010) and Mito-TEMPO (ALX-430-150-M005) were from Enzo Life 
Sciences. ML171 (4653) was from Tocris Bioscience. GKT137831 (S7171) was from 
Selleckchem. The following antibodies were used: Polyclonal rabbit anti-caspase-1 for 
mouse caspase-1 (1:1000) (SC-514, Santa Cruz Biotechnology), Polyclonal goat anti-IL-1β 
for mouse IL-1β (1:1000) (AF-401-NA, R&D Systems), Polyclonal rabbit anti-ASC for 
mouse ASC (1:1000) (ADI-905-173-100, Enzo Lifesciences), Monoclonal rabbit anti-
caspase-1 for human caspase-1 (1:1000) (3866, Cell signaling), Monoclonal mouse anti-
IL-1β for human IL-1β (1:1000) (MAB201, R&D Systems), Monoclonal rabbit anti-NOX4 
for human NOX4 and mouse NOX4 (1:1000) (ab133303, Abcam), Monoclonal mouse anti-
CPT1A for mouse CPT1A (1:1000) (ab128568, Abcam), Polyclonal rabbit anti-CPT1C for 
mouse CPT1C (1:1000) (ab87498, Abcam), Monoclonal rabbit anti-CD36 antibody for 
mouse CD36 (1:1000) (ab133625, Abcam), Polyclonal rabbit anti-ACOX1 antibody for 
mouse ACOX1 (1:1000) (ab59964, Abcam), Polyclonal rabbit anti-translocase of outer 
mitochondrial membrane 20 (TOMM20) antibody for human TOMM20 and mouse 
TOMM20 (1:1000) (SC-11415, Santa Cruz Biotechnology), Monoclonal mouse anti-β-actin 
(1:5000) (A5316, Sigma-Aldrich).
Preparation of Bovine Serum Albumin (BSA)-Conjugated Palmitate
Sodium palmitate (P9767, Sigma-Aldrich) or stearic acid (S4751, Sigma-Aldrich) was 
conjugated with fatty acid-free BSA (03117405001, Roche) at a 6:1 molar ratio according to 
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the manufacturer’s instructions (Seahorse Biosciences). BMDMs were treated with 
palmitate-BSA (500 µM, 2 h), stearic acid (500 µM, 2 h) or BSA as control after LPS 
incubation.
Cell culture
BMDMs were prepared as described1. Bone marrow collected from WT and Nox4−/− mice 
(male, 8–10 weeks old) femurs and tibias was plated on sterile petri dishes and incubated for 
7 d in DMEM media (Invitrogen) containing 10% (vol/vol) heat-inactivated FBS, 100 
units/ml penicillin, 100 mg/ml streptomycin, and 25% (vol/vol) conditioned medium from 
mouse L929 fibroblasts (CCL-1™, ATCC). WT and Nox4−/− BMDMs (5 × 106 cells in 100 
mm cell culture dish) were incubated with LPS (500 ng/ml, 4 h) and then were treated with 
NLRP3 inflammasome activators as described (nigericin (6.7 µM, 1 h), ATP (2 mM or 5 
mM, 30 min), silica (200 ng/ml, 16 h), MDP (200 ng/ml, 16 h), flagellin (200 ng/ml, 16 h) 
or A. hydrophila aerolysin (10 ng/ml, 0.5 h or 1 h)). Mice were injected with thioglycollate 
broth medium (1.0 ml, i.p.). After 4 d, peritoneal cells were collected from WT and 
Nox4−/−mice with cold PBS. Cells (1 × 106 cells in 6-well cell culture plates) were 
incubated for 2 h with DMEM medium containing 10% (vol/vol) heat-inactivated FBS, 
penicillin and streptomycin. Non-adherent cells are removed by gently washing with PBS. 
After cells were cultured for overnight, cells were incubated for 4 h with LPS and then were 
treated with NLRP3 inflammasome activators as described. The cell supernatants and cell 
lysates were collected and analyzed for the levels of IL-1β, IL-18 and TNF-α by ELISA. 
WT and Nox4−/− BMDMs were treated with medium containing KCl (100 mM, 1 h) for 
high extracellular [K+] before LPS and nigericin stimulation. WT BMDMs were treated with 
Mito-TEMPO (100 µM, 1 h) for inhibition of mtROS production before nigericin treatment 
after LPS stimulation. Primary BMDMs were not tested for mycoplasma.
Primary human macrophages
Primary human peripheral blood mononuclear cells (PBMCs) were isolated in healthy 
donors using Ficoll-Paque™. We confirmed consent was obtained from all human subjects. 
Primary human monocytes were isolated from PBMCs using Monocyte Isolation Kit II 
(130-091–153, Miltenyi Biotec) according to the manufacturer’s instructions. Primary 
human monocytes were differentiated to macrophages for 7 d in RPMI 1640 media 
(Invitrogen) containing 10% (vol/vol) heat-inactivated FBS, 100 units/ml penicillin, 100 
mg/ml streptomycin, and 5 ng/ml M-CSF (216-MC-025, R&D Systems). Primary human 
macrophages (1 × 106 cells in 6-well cell culture plates) were incubated for 4 h with LPS 
(500 ng/ml) and then were treated with NLRP3 inflammasome activators as described 
(nigericin (6.7 µM, 1 h) or ATP (5 mM, 30 min)). All analysis of human subjects was 
conducted according to the guidelines of the Weill Cornell Medical College Institutional 
Review Board (IRB) approval (protocol #: 1405015116A003; Weill Cornell Medical 
College, New York, New York, USA).
Immunoblot analysis
WT and Nox4−/− BMDMs, peritoneal macrophages or lung tissues were harvested and lysed 
in 2 × SDS loading buffer, NP40 Cell Lysis Buffer (FNN0021, Invitrogen) or Tissue 
Extraction Reagent I (FNN0071, Invitrogen) and then briefly sonicated. Lysates were 
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centrifuged at 15,300 g for 10 min at 4 °C, and the supernatants were obtained. The protein 
concentrations of the supernatants were determined using the Bradford assay (500-0006, 
Bio-Rad Laboratories). Proteins were electrophoresed on NuPAGE 4−12% Bis-Tris gels 
(Invitrogen) and transferred to Protran nitrocellulose membranes (10600001, GE Healthcare 
Life science). Membranes were blocked in 5% (wt/vol) bovine serum albumin (BSA) 
(9048-46-8, Santa Cruz Biotechnology) in TBS-T (TBS (170–6435, Bio-Rad Laboratories) 
and 1% (vol/vol) Tween-20 (170–6531, Bio-Rad Laboratories)) for 30 min at room 
temperature. Membranes were incubated with primary antibody diluted in 1% (wt/vol) BSA 
in TBS-T at 4 °C and then with the horseradish peroxidase (HRP)-conjugated secondary 
antibody (goat anti-rabbit IgG-HRP (SC-2004) (1:2500), goat anti-mouse IgG-HRP 
(SC-2005) (1:2500), goat anti-rabbit IgG-HRP (SC-2004) (1:2500) from Santa Cruz 
Biotechnology) diluted in TBS-T for 30 min at room temperature. The immunoreactive 
bands were detected by the SuperSignal West Pico Chemiluminescent Substrate (34078, 
Thermo Scientific). Mitochondrial fractions were isolated from WT and Nox4−/− BMDMs 
using a mitochondria/cytosol fraction kit (K265-25, Biovision) according to the 
manufacturer’s instructions.
ASC oligomerization and ASC speck formation
WT and Nox4−/− BMDMs (5 × 106 cells in 100 mm cell culture dish) were harvested and 
lysed in 500 µl of lysis buffer (20 mM HEPES–KOH, pH 7.5, 150 mM KCl, 1% NP-40) as 
described previously29,30. Lysates were centrifuged at 330 × g for 10 min at 4 °C. The 
pellets were washed in 1 ml of PBS and resuspended in 500 µl of PBS. 2 mM 
disuccinimydyl suberate (DSS) was added to the resuspended pellets, which were incubated 
for 30 min with rotation at room temperature. Samples were then centrifuged at 330 × g for 
10 min at 4 °C. The supernatant was removed, and the cross-linked pellets were resuspended 
in 50 µl of Laemmli sample buffer. Samples were analyzed by immunoblot analysis using 
polyclonal ASC antibody (ADI-905-173-100, Enzo Lifesciences). WT and Nox4−/−BMDMs 
were seeded on chamber slides. After stimulation, cells were fixed with 4% 
paraformaldehyde and then incubated with polyclonal ASC antibody (ADI-905-173-100, 
Enzo Lifesciences) for 16 h followed by DAPI (P36962, ThermoFisher Scientific) staining 
as described previously29,30. ASC specks were analyzed by Zeiss LSM880 laser scanning 
confocal microscope and quantified using ImageJ software. The graph represents the 
quantification of cells with specks in five distinct areas.
Cytokine analysis
Supernatants from WT and Nox4−/− BMDMs or peritoneal macrophages and plasma or lung 
tissues from WT and Nox4−/− mice were measured for mouse IL-1β (MLB00C, R&D 
systems), mouse IL-18 (7625, R&D systems), mouse TNF-α (MTA00B, R&D systems) 
according to the manufacturer’s instructions. Supernatants from primary human 
macrophages were measured for human IL-1β (DLB50, R&D systems), human IL-18 
(7620, R&D systems) and human TNF-α (DTA00C, R&D systems) according to the 
manufacturer’s instructions.
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Quantitative real-time PCR
Total RNA was isolated from WT and Nox4−/− BMDMs or lung tissues using the TRIzol 
reagent (15596-018, Invitrogen) according to the manufacturer’s instructions. For 
quantitative RT-PCR, cDNA was synthesized from 4 µg of total RNA using random 
hexamers and SuperScript Reverse Transcriptase II® (18064-014, Invitrogen) according to 
the manufacturer’s instructions. A 10 µl mixture containing the diluted cDNA and a set of 
gene-specific primers was mixed with 10 µl of 2 × SYBR Green PCR Master Mix (4309155, 
Applied Biosystems) and then subjected to RT–PCR quantification using the ABI PRISM 
7500 real-time PCR system (Applied Biosystems). The following primers were used: mouse 
Nox1 forward, 5’-TGAACAACAGCACTCACCAATGCC-3’ and reverse, 5’-TCATTG 
TCCCACATTGGTCTCCCA-3’; mouse Nox2 forward, 5’-CCCTTTGGTACAGCCAGT 
GAAGAT-3’ and reverse, 5’-CAATCCCGGCTCCCACTAACATCA-3’; mouse Nox3 
forward, 5’-TTGTGGCACACTTGTTCAACCTGG-3’ and reverse, 5’-TCACACGCA 
TACAAGACCACAGGA-3’; mouse Nox4 forward, 5’-TCATGGATCTTTGCCTCG 
AGGGTT-3’ and reverse, 5’-AGTGACTCCTCAAATGGGCTTCCA-3’; mouse Duox1 
forward, 5’-CACCATTGGGACCCTTTGCTGTTT-3’ and reverse, 5’-AGCCTTTCATGA 
AGACCACCAGGA-3’; mouse Duox2 forward, 5’-AACCACCTATCTGGGCATCAT 
CCT-3’ and reverse, 5’-AGCTGCCATGGATGATGATCTGGA-3′; mouse Cpt1a forward, 
5’-GGTCTTCTCGGGTCGAAAGC-3’ and reverse, 5’-TCCTCCCACCAGTCACTCAC-3’; 
mouse Gapdh forward, 5’-GGTGAAGGTCGGTGTGAACGGA-3’ and reverse, 5’-
CCAAAGTTGTCATGGATGACCTTGG-3’.
Transduction of shRNA or gRNA/Cas9 plasmid
For stable knockdown of human NOX4, two independent NOX4-targeted gRNAs (S19475 
and S19481, GeneScript) were used. Primary human macrophages (2 × 105 cells in 6-well 
cell culture plates) were seeded and were transduced with gRNA/Cas9 lentiviral plasmids 
against human NOX4 or pLentiCRISPR v2 for control. For stable knockdown of mouse 
Cpt1a, two independent Cpt1a-targeted gRNAs (C91581 and C92251, GeneScript) were 
used. WT BMDMs (5 × 105 cells in 6-well cell culture plates) were seeded and were 
transduced with gRNA/Cas9 lentiviral plasmids against mouse Cpt1a or pLentiCRISPR v2 
for control. For stable knockdown of mouse Cpt1a, two independent small hairpin RNA 
(TRCN0000305935 and TRCN0000110598, Sigma-Aldrich) were used. WT peritoneal 
macrophages (5 × 105 cells in 6-well cell culture plates) were seeded and were transduced 
with shRNA lentiviral constructs against mouse Cpt1a or non-target shRNA (SHC016, 
Sigma-Aldrich) for control. For stable over-expression of mouse Nox4, lenti ORF clone of 
Nox4 (Myc-DDK-tagged) (MR227192, Origene) was used. For stable over-expression of 
mouse CPT1A, lenti ORF clone of Cpt1a (Myc-DDK-tagged) (MR210568L1, Origene) was 
used. For stable over-expression of mouse NLRP3, lenti ORF clone of Nlrp3 (Myc-DDK-
tagged) (MR227218, Origene) was used. For AIM2 inflammasome activation, LPS-primed 
WT and Nox4−/− BMDMs or peritoneal macrophages were transfected with poly(dA:dT) (1 
µg/ml) (Sigma-Aldrich) using Lipofectamine® with Plus reagent (15338-100, Invitrogen) 
according to the manufacturer’s instructions.
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Mitochondrial ROS production assay
Mitochondrial ROS were measured by MitoSOX (M36008, Invitrogen) staining. WT and 
Nox4−/− BMDMs or peritoneal macrophages were incubated with mitochondrial 
superoxide-specific stain MitoSOX (5 µM) for 15 min at 37 °C. WT and Nox4−/− BMDMs 
or peritoneal macrophages were washed with PBS, treated with trypsin and resuspended in 
PBS containing 1% (vol/vol) heat-inactivated FBS. Data were acquired with a BD Accuri™ 
C6 Cytometer (BD Biosciences) and were analyzed with FlowJo analytical software 
(TreeStar).
Metabolomic analysis
WT BMDMs stimulated with LPS and ATP. All samples (n = 6 per group) were harvested 
with PBS. All samples were inventoried and immediately stored at −80 °C. At the time of 
analysis, samples were extracted and prepared for analysis using a standard solvent 
extraction method (Metabolon). The extracted samples were split into equal parts for 
analysis on the GC/MS and LC/MS/MS platform, according to the manufacturer’s 
instructions (Metabolon).
Fatty acid assay
Free fatty acid levels in WT and Nox4−/− BMDMs or peritoneal macrophages were 
measured using the Free Fatty Acid Quantification Colorimetric/Fluorometric Kit 
(K612-100, Biovision) according to the manufacturer’s instructions. Intracellular acetyl-
CoA levels in WT and Nox4−/− BMDMs or peritoneal macrophages were measured by 
PicoProbe™ Acetyl-CoA Fluorometric Assay Kit (K317-100, Biovision) according to the 
manufacturer’s instructions.
Fatty acid oxidation assay
For the fatty acid oxidation assay, WT and Nox4−/− BMDMs (5 × 104 cells/well) were 
plated on XF96 cell culture microplates (101085–004, Seahorse Bioscience). The OCR as 
parameters of mitochondrial fatty acid oxidation was measured on a Seahorse XF96 
bioanalyzer, using the XF Palmitate-BSA FAO Substrate (102720-100, Seahorse Bioscience) 
and Mito Stress Test Kit (103015-100, Seahorse Bioscience) according to the manufacturer’s 
instructions. The OCR for oxidation of palmitate-BSA was measured in WT and Nox4−/− 
BMDMs treated with palmitate-BSA (180 µM), etomoxir (40 µM) and oligomycin (1 µM).
Glycolytic function assay
For the glycolytic function assay, WT and Nox4−/− BMDMs (5 × 104 cells/well) were plated 
on XF96 cell culture microplates (101085-004, Seahorse Bioscience). The ECAR as 
parameters of glycolytic flux was measured on a Seahorse XF96 bioanalyzer, using the XF 
Glycolysis Stress Test Kit (102194–100, Seahorse Bioscience) according to the 
manufacturer’s instructions. The ECAR was measured in WT and Nox4−/− BMDMs treated 
with glucose (10 mM), oligomycin (2 µM) and 2DG (10 mM).
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Statistical analysis
All statistical tests of data were analyzed by Student’s two-tailed t-test for comparison of 
two groups, analysis of variance (ANOVA) (with post hoc comparisons using Dunnett’s test) 
using a statistical software package (GraphPad Prism version 4.0) for comparison of 
multiple groups. Survival analyses were performed using a log-rank test using a statistical 
software package (GraphPad Prism version 4.0). Sample size (number of mice) was 
determined on the basis of our previous studies7,53. P values of less than 0.05 were 
considered statistically significant. All data are mean ± s.d., combined from three 
independent experiments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Deficiency of NOX4 suppresses NLRP3 inflammasome activation. (a,b) The results of 
ELISA from LPS-primed WT and Nox4−/− BMDMs for (a) IL-1β, IL-18 and TNF-α after 
stimulation with nigericin, ATP, silica, MDP or flagellin and (b) for IL-1β after stimulation 
with poly(dA:dT). (c) Immunoblot analysis for caspase-1 and IL-1β from LPS-primed WT 
and Nox4−/− BMDMs stimulated with nigericin. (d) Immunoblot analysis for NOX4 in 
mitochondrial fraction, caspase-1 and IL-1β in cytosolic fraction and (e) ELISA for IL-1β 
and IL-18 from primary human macrophages transduced with lentivirus expressing two 
independent NOX4-targeted gRNAs (NOX4 gRNA #1 and NOX4 gRNA #2) and control 
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plasmid (Control), and stimulated with LPS and nigericin or ATP. (f) ELISA for IL-1β, 
IL-18 and TNF-α and (g) Immunoblot analysis for NOX4 and caspase-1 in lung tissues (100 
µg) from WT and Nox4−/− mice after infection of S. pneumoniae or PBS for 24 h (PBS, n = 
3 and S. pneumoniae, n = 10). (h) Survival curve of S. pneumoniae infection was determined 
in WT and Nox4−/− mice (WT, n = 30 and Nox4−/−, n = 30, P = 0.0121 by log-rank test). 
TOMM20 and β-actin served as the standard. Data are derived from n = 6 (a); n = 3 (b); or n 
= 6 (c) mice and n = 3 (d) human subjects. All data are mean ± s.d., **P < 0.01 by ANOVA. 
*P < 0.05 by ANOVA. Data are representative of three independent experiments and each 
carried out in triplicate.
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Figure 2. 
NOX4 regulates FAO during NLRP3 inflammasome activation. (a) Immunoblot analysis for 
NOX4 in mitochondrial (Mito) and cytosolic (Cyto) fractions from LPS-primed WT 
BMDMs stimulated with nigericin or ATP. (b) Flow cytometry analysis of WT and Nox4−/− 
BMDMs stained with MitoSOX and then treated with nigericin after LPS. (c) FFA levels 
and (d) OCR for oxidation of palmitate-BSA (PA-BSA) from WT and Nox4−/− BMDMs 
stimulated with LPS and nigericin. (e) Immunoblot analysis for caspase-1 and IL-1β and (f) 
ELISA for IL-1β, IL-18 and TNF-α and (g) Acetyl-CoA levels from LPS-primed WT and 
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Nox4−/− BMDMs incubated with PA–BSA, nigericin or ATP. (h) Immunoblot analysis (left) 
for DSS–cross-linked ASC, ASC, caspase-1 and IL-1β from WT and Nox4−/− BMDMs 
stimulated with LPS and nigericin. Representative immunofluorescence images (n = 5 per 
group) (right) of ASC speck formation (white arrows) in WT and Nox4−/− BMDMs 
stimulated with LPS and nigericin (right) or control (left). Scale bars, 20 µm. (i) FFA and 
acetyl-CoA levels and (j) Immunoblot analysis for NOX4, caspase-1 and IL-1β and ELISA 
for IL-1β, IL-18 and TNF-α in control and Nox4 over-expressed peritoneal macrophages 
stimulated with LPS and nigericin or ATP. All data are mean ± s.d., *P < 0.05 by ANOVA. 
Data are derived from n = 5 (a); n = 3 (b); n = 5 (c); n = 6 (d–f); n = 5 (g); n = 6 (h) or n = 
10 (i,j) mice with three independent experiments.
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Figure 3. 
NOX4 regulates CPT1A in NLRP3 inflammasome activation. (a) Immunoblot analysis for 
CPT1A and CPT1C in mitochondrial fractions and ACOX1 in cytosolic fractions from WT 
and Nox4−/− BMDMs stimulated with LPS and nigericin. Data are normalized to TOMM20. 
(b) Quantitative PCR analysis for Nox4 gene expression from WT BMDMs in medium 
containing KCl (100 mM, 1 h) stimulated with LPS and nigericin. (c) Immunoblot analysis 
for NOX4 and CPT1A in mitochondrial fraction and caspase-1 and IL-1β in cytosolic 
fraction from WT BMDMs in medium containing KCl stimulated with LPS and nigericin. 
(d) Immunoblot analysis for CPT1A in mitochondrial fractions and caspase-1 and IL-1β in 
cytosolic fractions from WT BMDMs pre-treated with Mito-TEMPO (100 µM, 1 h) before 
nigericin treatment after LPS stimulation. (e) OCR for oxidation of palmitate-BSA was 
measured in WT BMDMs pre-treated with Mito-TEMPO before nigericin treatment after 
LPS stimulation. (f) Intracellular FFA levels in WT BMDMs pre-treated with Mito-TEMPO 
before nigericin treatment after LPS stimulation. TOMM20 and β-actin served as the 
standard. Data are derived from n = 5 (a); n = 6 (b,c); n = 3 (d); or n = 5 (e,f) mice. All data 
are mean ± s.d., **P < 0.01 by ANOVA. *P < 0.05 by ANOVA. Data are representative of 
three independent experiments and each carried out in triplicate.
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Figure 4. 
Inhibition of FAO suppresses NLRP3 inflammasome activation. (a) Immunoblot analysis for 
CPT1A in mitochondrial fractions, caspase-1 and IL-1β in cytosolic fractions and (b) 
ELISA for IL-1β, IL-18 and TNF-α from WT BMDMs transduced with lentivirus 
expressing two independent Cpt1a-targeted gRNAs (Cpt1a gRNA#1 and gRNA#2) and 
control plasmid (Control), and stimulated with LPS and nigericin. (c) Immunoblot analysis 
for DSS–cross-linked ASC of cross-linked cytosolic pellets, and ASC, caspase-1 and IL-1β 
of cell lysates from WT BMDMs transduced with lentivirus expressing Cpt1a-targeted 
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gRNA (Cpt1a gRNA) and control plasmid (Control), and stimulated with LPS and nigericin. 
(d) Immunoblot analysis for CPT1A in mitochondrial fractions, caspase-1 and IL-1β in 
cytosolic fractions from control and Cpt1a over-expressed in Nox4−/− BMDMs stimulated 
with LPS and nigericin. (e) ELISA for IL-1β, IL-18 and TNF-α from control and Cpt1a 
over-expressed in Nox4−/− BMDMs stimulated with LPS and nigericin or ATP. (f) 
Immunoblot analysis for caspase-1 and IL-1β and (g) ELISA for IL-1β, IL-18 and TNF-α 
from WT BMDMs pre-treated with etomoxir (200 µM, 1 h) or distilled water (Control), 
followed by incubation with palmitate-BSA (PA-BSA), nigericin or ATP after LPS 
stimulation. TOMM20 and β-actin served as the standard. Data are derived from n = 6 (a,b); 
n = 5 (c); n = 8 (d,e); or n = 6 (f,g) mice. All data are mean ± s.d., **P < 0.01 by ANOVA. 
*P < 0.05 by ANOVA. Data are representative of three independent experiments and each 
carried out in triplicate.
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Figure 5. 
GKT137831 suppresses NLRP3 inflammasome activation. (a) ELISA for IL-1β, IL-18 and 
TNF-α from WT peritoneal macrophages pre-treated with GKT137831 (20 µM, 1 h) or 
DMSO before LPS stimulation and followed with ATP, nigericin, silica, MDP or flagellin. 
(b) ELISA for IL-1β and TNF-α from WT peritoneal macrophages pre-treated with 
GKT137831 (0, 5 10, 20, 50 or 100 µM, 1 h) before LPS and nigericin. (c) Flow cytometry 
analysis of WT peritoneal macrophages stained with MitoSOX and then treated with 
GKT137831 or DMSO before LPS and nigericin. (d) Immunoblot analysis forCPT1A in 
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mitochondrial fractions and (e) OCR for oxidation of palmitate-BSA (PA-BSA) and (f) FFA 
levels from WT BMDMs pre-treated with GKT137831 or DMSO before nigericin 
stimulation after LPS. TOMM20 served as the standard. (g) ELISA for IL-1β, IL-18 and 
TNF-α from WT BMDMs pre-treated with GKT137831 or DMSO, followed by incubation 
with PA-BSA, nigericin or ATP after LPS. (h) ELISA for IL-1β, IL-18 and TNF-α in lung 
tissues (100 µg) from WT mice after i.p. injection of GKT137831 (20 mg/kg, 3 h) or 
DMSO, then infection of S. pneumoniae or PBS for 24 h (PBS, n = 3 and S. pnumoniae, n = 
7). Data are derived from n = 6 (a,b); n = 5 (c); n = 3 (d); n = 5 (e); or n = 6 (f,g) mice. All 
data are mean ± s.d., **P < 0.01 by ANOVA. *P < 0.05 by ANOVA. Data are representative 
of three independent experiments and each carried out in triplicate.
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Figure 6. 
Inhibition of NOX4 suppresses NLRP3 inflammasome activation. (a) Flow cytometry 
analysis of WT peritoneal macrophages stained with MitoSOX and then treated with 
VAS-2870 (1 µM, 1 h) or DMSO before nigericin stimulation after LPS. (b) Immunoblot 
analysis for CPT1A in mitochondrial fractions and (c) OCR for oxidation of palmitate-BSA 
(PA-BSA) from WT BMDMs pre-treated with VAS-2870 or DMSO before nigericin 
stimulation after LPS. (d) FFA levels in WT BMDMs pre-treated with VAS-2870 before 
nigericin stimulation after LPS. (e) ELISA for IL-1β, IL-18 and TNF-α from WT BMDMs 
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pre-treated with VAS-2870 or DMSO, followed by incubation with PA-BSA, nigericin or 
ATP after LPS stimulation. (f,g) Immunoblot analysis for caspase-1 and IL-1β and (h) 
ELISA for IL-1β, IL-18 and TNF-α from primary human macrophages pre-treated with 
GKT137831 (20 µM, 1 h), VAS-2870 (2 µM, 1 h) or DMSO before nigericin or ATP 
stimulation after LPS. (i) ELISA for IL-1β, IL-18 and TNF-α in lung tissues (100 µg) from 
WT mice after i.p. injection of VAS-2870 (10 mg/kg, 3 h) or DMSO, then infection of S. 
pneumoniae or PBS for 24 h (PBS, n = 3 and S. pnumoniae, n = 7). Data are derived from n 
= 5 (a); n = 3 (b); n = 5 (c,d); n = 6 (e) mice; or n = 3 (f–h) human subjects. All data are 
mean ± s.d., **P < 0.01 by ANOVA. *P < 0.05 by ANOVA. Data are representative of three 
independent experiments and each carried out in triplicate.
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